Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC

Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC

Background and objectiveSintilimab has superior efficacy and safety in patients with advanced or metastatic squamous non-small cell lung cancer (NSCLC), but its cost-effectiveness in China is unclear. This study is to evaluate the cost-effectiveness of sintilimab plus chemotherapy vs. pembrolizumab...

Full description

Bibliographic Details
Main Authors: Pingyu Chen, Xintian Wang, Shengwen Zhu, Hongchao Li, Mingjun Rui, Yingcheng Wang, Haikui Sun, Aixia Ma
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Public Health
Subjects:
economic evaluation
NSCLC
PD-1 inhibitors
pembrolizumab
sintilimab
Online Access:https://www.frontiersin.org/articles/10.3389/fpubh.2022.956792/full

Internet

https://www.frontiersin.org/articles/10.3389/fpubh.2022.956792/full

Similar Items